Premium
Intravesical Evans Bacille Calmette‐Guérin in the Treatment of Carcinoma in situ
Author(s) -
CUMMING J. A.,
HARGREAVE T. B.,
WEBB J. N.,
McINTYRE MARGARET A.,
CHISHOLM G. D.
Publication year - 1989
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1989.tb05186.x
Subject(s) - medicine , carcinoma in situ , saline , urology , carcinoma , bcg vaccine , surgery , gastroenterology , pathology , tuberculosis
Summary— We report our experience in the treatment of carcinoma in situ of the urinary bladder using Evans strain Bacille Calmette‐Guérin (BCG). The mean period of follow‐up was 30 months; 18 patients received intravesical therapy and 16 of these were evaluable. They received 8 weekly instillations of 60 mg Evans strain BCG in 50 ml of saline. No intradermal BCG was given. The response rate was 93.75% at 3 months; this declined to 57% at 2 years. The complications of therapy were frequent but mild. Seven patients failed to complete the course. These results were comparable to those obtained with other strains of Bacille Calmette‐Guérin.